Aspen Aerogels, Inc. (NYSE:ASPN) Receives $19.11 Consensus PT from Brokerages

Aspen Aerogels, Inc. (NYSE:ASPN) has received an average rating of “Buy” from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $19.11.

ASPN has been the topic of a number of recent research reports. Craig Hallum reduced their target price on Aspen Aerogels from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, February 14th. Canaccord Genuity Group decreased their price objective on Aspen Aerogels from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, February 14th. TD Cowen raised shares of Aspen Aerogels to a “strong-buy” rating in a research note on Tuesday, March 11th. StockNews.com raised shares of Aspen Aerogels to a “sell” rating in a research note on Wednesday, February 19th. Finally, Barclays cut their price objective on shares of Aspen Aerogels from $25.00 to $13.00 and set an “overweight” rating for the company in a research report on Wednesday, February 19th.

Aspen Aerogels Price Performance

ASPN stock opened at $5.82 on Wednesday. The firm has a 50 day moving average of $6.30 and a 200-day moving average of $11.18. The company has a market cap of $477.85 million, a price-to-earnings ratio of 36.38 and a beta of 2.72. The company has a current ratio of 2.93, a quick ratio of 2.48 and a debt-to-equity ratio of 0.27. Aspen Aerogels has a 12-month low of $4.80 and a 12-month high of $33.15.

Aspen Aerogels (NYSE:ASPN) last issued its quarterly earnings data on Wednesday, February 12th. The construction company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.11. Aspen Aerogels had a return on equity of 7.49% and a net margin of 2.95%. As a group, equities analysts expect that Aspen Aerogels will post 0.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Aspen Aerogels

Institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC lifted its holdings in shares of Aspen Aerogels by 4,757.8% in the 4th quarter. Millennium Management LLC now owns 1,622,022 shares of the construction company’s stock worth $19,270,000 after purchasing an additional 1,588,632 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Aspen Aerogels during the fourth quarter valued at $13,122,000. Alyeska Investment Group L.P. bought a new position in shares of Aspen Aerogels during the fourth quarter worth about $9,504,000. Dendur Capital LP acquired a new stake in shares of Aspen Aerogels in the 4th quarter worth about $9,207,000. Finally, Renaissance Technologies LLC lifted its position in Aspen Aerogels by 472.4% in the 4th quarter. Renaissance Technologies LLC now owns 766,400 shares of the construction company’s stock valued at $9,105,000 after purchasing an additional 632,500 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.